GRACELL BIOTECHNOLOGIES-ADR (GRCL) Stock Price, Quote, News and Overview
NASDAQ:GRCL - Nasdaq - US38406L1035 - ADR - Currency: USD
GRCL Quote, Performance and Key Statistics
10.25
+0.01 (+0.05%)
The current stock price of GRCL is 10.25 USD. In the past month the price increased by 1.59%. In the past year, price increased by 412.5%.
GRCL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About GRCL
Company Profile
Gracell Biotechnologies, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai and currently employs 314 full-time employees. The company went IPO on 2021-01-08. The firm is primarily focused on disrupting conventional approaches to chimeric antigen receptor (CAR) thymus (T) cell therapies by leveraging its technology platforms FasTCAR and TruUCAR. With FasTCAR, the Company is able to deliver younger, less exhausted T cells for autologous cell therapies with enhanced activities and next-day manufacturing. With TruUCAR, the Company is able derive T cells from non-human leukocyte antigen (HLA)-matched healthy donors to generate allogeneic CAR-T cell therapies. The firm is levering its technology platform to develop various drug candidates, including GC012F, GC019F, GC007F, GC027 and GC007g.
Company Info
GRACELL BIOTECHNOLOGIES-ADR
Building 3, 418 Guilin Road, Xuhui District
Shanghai SHANGHAI 215123 CN
CEO: William Wei Cao
Employees: 314
Company Website: https://www.gracellbio.com/
Phone: 862164031522
GRACELL BIOTECHNOLOGIES-ADR / GRCL FAQ
What is the stock price of GRACELL BIOTECHNOLOGIES-ADR today?
The current stock price of GRCL is 10.25 USD. The price increased by 0.05% in the last trading session.
What is the ticker symbol for GRACELL BIOTECHNOLOGIES-ADR stock?
The exchange symbol of GRACELL BIOTECHNOLOGIES-ADR is GRCL and it is listed on the Nasdaq exchange.
On which exchange is GRCL stock listed?
GRCL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GRACELL BIOTECHNOLOGIES-ADR stock?
15 analysts have analysed GRCL and the average price target is 10.76 USD. This implies a price increase of 4.99% is expected in the next year compared to the current price of 10.25. Check the GRACELL BIOTECHNOLOGIES-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GRACELL BIOTECHNOLOGIES-ADR worth?
GRACELL BIOTECHNOLOGIES-ADR (GRCL) has a market capitalization of 989.87M USD. This makes GRCL a Small Cap stock.
How many employees does GRACELL BIOTECHNOLOGIES-ADR have?
GRACELL BIOTECHNOLOGIES-ADR (GRCL) currently has 314 employees.
What are the support and resistance levels for GRACELL BIOTECHNOLOGIES-ADR (GRCL) stock?
GRACELL BIOTECHNOLOGIES-ADR (GRCL) has a support level at 10.25 and a resistance level at 10.36. Check the full technical report for a detailed analysis of GRCL support and resistance levels.
Should I buy GRACELL BIOTECHNOLOGIES-ADR (GRCL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GRCL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GRCL, evaluating the profitability, health, valuation and growth aspects
- GRACELL BIOTECHNOLOGIES-ADR (GRCL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GRACELL BIOTECHNOLOGIES-ADR (GRCL) Sales and EPS estimates to see what analysts future expectations are.
- GRACELL BIOTECHNOLOGIES-ADR (GRCL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GRACELL BIOTECHNOLOGIES-ADR (GRCL) Insider and Institutional Ownership to learn about the owners and their transactions.
- GRACELL BIOTECHNOLOGIES-ADR (GRCL) Stock Chart to make your own analysis
- GRACELL BIOTECHNOLOGIES-ADR (GRCL) Latest news and press-releases to stay up to date.
Does GRACELL BIOTECHNOLOGIES-ADR (GRCL) stock pay dividends?
GRCL does not pay a dividend.
When does GRACELL BIOTECHNOLOGIES-ADR (GRCL) report earnings?
GRACELL BIOTECHNOLOGIES-ADR (GRCL) will report earnings on 2024-03-11, after the market close.
What is the Price/Earnings (PE) ratio of GRACELL BIOTECHNOLOGIES-ADR (GRCL)?
GRACELL BIOTECHNOLOGIES-ADR (GRCL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.18).
GRCL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GRCL. When comparing the yearly performance of all stocks, GRCL is one of the better performing stocks in the market, outperforming 99.35% of all stocks.
GRCL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GRCL. GRCL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GRCL Financial Highlights
Over the last trailing twelve months GRCL reported a non-GAAP Earnings per Share(EPS) of -0.18. The EPS decreased by -4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.64% | ||
| ROE | -52.9% | ||
| Debt/Equity | 0.12 |
GRCL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 79% to GRCL. The Buy consensus is the average rating of analysts ratings from 15 analysts.